News Focus
News Focus
Followers 114
Posts 3804
Boards Moderated 0
Alias Born 06/02/2009

Re: steve060688 post# 99784

Monday, 02/08/2010 1:07:40 PM

Monday, February 08, 2010 1:07:40 PM

Post# of 216412
I agree. Paul did mention that the application was filed before October but that the amendment had yet to be filed.

I look at many positive signs. Look at the talent and connections of the development team. Going through the patent application I see many references to clinical practices undertaken by Korean company. It may not be approved tomorrow but there are a lot of positives here.

The team behind the Bioharp:

-Professor of KAIST (Korean Advanced Institute of Science and Technology ) since 2004
-Technology Policy Advisor of ADD (Agency for Defense Development) 2004
-Visiting professor of Dongguk University since 2003
-Head, electronic & communication division in ADD (Agency for Defense Development)
-Chairman, Genohco.,Inc
-CEO, Genohco.,Inc
http://www.gobizkorea.com/blog/index.do?blogid=genohco
-CEO, Samwoo Telecommunication Industry in Korea from 1995 to 2004
-Managing Director, Satellite Communication Department of KT Corporation in Korea from 1991 to 2006
-Senior engineer, electronic & communication division in ADD (Agency for defense evelopment)

Pre-clinical testing:

-under the pre-clinical test regulations of the Pre-Clinical Research Center (KGLP Approval) of Chemon Inc

-0171]The kind of cancer cells were a human cancer cell line such as lung cancer (A549), colon cancer (HCT15), melanoma (LOX-IMVI), prostate carcinoma (PC-3), and breast cancer (MDA-MB-231), which were all obtained from the Korea Research Institute of Bioscience & Biotechnology in the form of freezing vials, and kept in a liquid nitrogen tank in a cell culture room of Pharmacology and Medicine Laboratory in the Pre-Clinical Researching center (KGLP Approval) of Chemon Inc

-The inventor of the present invention measured carcinogenesis in the animals by group from the first day of the cancer cell transplantation under the pre-clinical test regulations of the Pre-Clinical Research Center (KGLP Approval) of Chemon Inc. by using the early cancer diagnostic device manufactured with the functions of the biosensor

-[0159]Mice to be tested were specific pathogen free BALB/C nude mice (Athymic BALB/C Nude Mouse), which were 8 weeks old female mice removed of thymus (available from Central Lab. Animals Inc., Korea
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y